NEURONAX is a biopharmaceutical company based in Clermont-Ferrand and Lyon (France).
Our vocation is to develop first-in-class innovative drugs to treat patients with traumatic or severe neurological disorders with high unmet medical needs. Our ambition is to improve the recovery of the functionality and the quality of life for patients.
Our lead product (NX210) is a very promising drug with a high potential in many neurological disorders. This is a peptide with multi-functional action and its efficacy is supported by several pre-clinical proof of concept studies. We observed in vivo its capacity to regrow the nerve fibers after traumatic spinal cord injuries and to support functional recovery. The properties of NX210, and its patented analogs, have driven us with a strong rational to investigate in neurological disorders as Multiple Sclerosis, Alzheimer, Parkinson,..
A first clinical study (phase I) in human is expected to start soon in patients with Acute Spinal Cord Injury.
The interaction between glia and neurons is essential in development, function and repair of the central nervous system (CNS). In fact, signaling of glia is critical for axonal guidance and synaptogenesis at early developmental stages, whereas glial cells play a prominent role in the pathology of...
NX210 is a patented peptide deduced from the thrombospondin repeat domains (TSRs) of the SCO-spondin, and a first-in class multi-functional agent able to prevent neural cell death and to promote neurite outgrowth. Our data show that NX210 is able to promote neurite fasciculation and...
Neurological disorders are diseases of the central and peripheral nervous system including epilepsy, Alzheimer disease and other dementias, Parkinson’s disease, multiple sclerosis, and other myelin disorders, but also cerebrovascular diseases like stroke, neuroinfections, brain tumors and trau...